# Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

> **NCT00876655** · PHASE1 · COMPLETED · sponsor: **Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** TR-701 di-sodium phosphate salt
- **DRUG:** TR-701 free acid phosphate

## Key facts

- **NCT ID:** NCT00876655
- **Lead sponsor:** Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876655, "Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00876655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*